Death rates in the U.S. due to Leukodystrophies with pediatric forms

Amy L Barczykowski1,2, Thomas J Langan3,4, Adeline Vanderver5,6

  • 1Population Health Observatory, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York, USA.

Insights

Leukodystrophies (LDs) impact children and adults, with pediatric fatality cases declining then stabilizing. This study provides crucial epidemiological data for rare disease research and newborn screening programs.

Area of Science:

  • Neurology
  • Epidemiology
  • Genetics

Background:

  • Leukodystrophies (LDs) are a group of rare genetic disorders affecting the brain's white matter.
  • Accurate epidemiological data for LDs, particularly those with pediatric forms, are often lacking.
  • Understanding mortality rates and prevalence is essential for resource allocation and patient care.

Observation:

  • National mortality and state death certificate records were analyzed for 23 LDs with pediatric forms.
  • ICD-10 codes identified deaths related to LDs, with data categorized using state-specific proportions.
  • Calculations incorporated population sizes and average lifespans to estimate disease-specific rates.

Findings:

  • An estimated 1.513 per million children (0-17 years) and 0.194 per million adults (≥18 years) died from these LDs.
  • The average age of death for pediatric LD cases was 5.2 years, and 42.3 years for adults.
  • Prevalence of pediatric fatality cases decreased from 1999-2007, then remained constant at 6.2 per million children annually through 2012.

Implications:

  • The findings provide vital epidemiological information for rare diseases like LDs.
  • This data supports newborn screening programs, research funding, and specialized care centers.
  • The methodology is adaptable for studying other rare diseases, enhancing public health surveillance.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
62
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
84
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
53
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.2K
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.5K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
71